<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01548846</url>
  </required_header>
  <id_info>
    <org_study_id>TOQUAL</org_study_id>
    <nct_id>NCT01548846</nct_id>
  </id_info>
  <brief_title>Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract</brief_title>
  <acronym>TOQUAL</acronym>
  <official_title>Impact of Tomotherapy on Xerostomia and Quality of Life of Patients With Cancer of the Upper Aero-digestive Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Francois Baclesse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study whose main objective is to evaluate prospectively the proportion of patients
      with severe xerostomia one year after treatment with tomotherapy for head and neck cancer.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of recrutment
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the proportion of patients with xerostomia</measure>
    <time_frame>12 months after completion of radiotherapy.</time_frame>
    <description>Estimate the proportion of patients with xerostomia of grade greater than or equal to 2 assessed by the scale of late toxicity RTOG / EORTC 12 months after completion of radiotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of acute and late xerostomia</measure>
    <time_frame>after 3, 6 and 12 months after radiotherapy</time_frame>
    <description>Evaluation of acute xerostomia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of salivary flow with and without stimulation</measure>
    <time_frame>at 3, 6 and 12 months after end of radiotherapy</time_frame>
    <description>Measurement of salivary flow with and without stimulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the incidence of acute side effects of radiotherapy</measure>
    <time_frame>Weekly during radiotherapy</time_frame>
    <description>Evaluation of the incidence of acute and late side effects of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the incidence of late side effects of radiotherapy</measure>
    <time_frame>At 3, 6 and 12 months after radiotherapy</time_frame>
    <description>Evaluation of the incidence of late side effects of radiotherapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of quality of life and fatigue</measure>
    <time_frame>At 3, 6 and 12 months after radiotherapy</time_frame>
    <description>Evaluation of quality of life and fatigue</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of overall survival and progression-free survival</measure>
    <time_frame>at 3, 6 and 12 months after radiotherapy</time_frame>
    <description>Evaluation of overall survival and progression-free survival</description>
  </secondary_outcome>
  <enrollment type="Actual">11</enrollment>
  <condition>Head and Neck Cancer</condition>
  <condition>Radiotherapy by Tomotherapy Exclusive</condition>
  <condition>With or Without Concurrent Chemotherapy</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Tomotherapy</intervention_name>
    <description>Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient (e) old (e) over 18 years

          -  Patients with squamous cell carcinoma of head and neck (oral cavity, oropharynx,
             lymphadenopathy without gateway) histologically proven.

          -  Patient targeted for head and neck radiotherapy by Tomotherapy exclusive with or
             without concurrent chemotherapy (containing platinum)

          -  Indication of head and neck radiotherapy bilateral

          -  All of the TNM stage except metastatic

          -  Patient has signed informed consent for participation in the study

          -  Mastery of the French language

        Exclusion Criteria:

          -  History of head and neck radiotherapy

          -  Indication of head and neck radiotherapy unilateral

          -  Personal history of malignant tumors uncontrolled over the past 5 years

          -  History of oral sicca syndrome

          -  Surgical removal of one or more salivary glands (parotid, submandibular gland,
             sublingual gland)

          -  Concomitant treatment with amifostine

          -  Concomitant treatment with cetuximab

          -  Primary tumor of the salivary glands

          -  Head and neck hyperfractionated radiotherapy and / or accelerated

          -  Head and neck radiotherapy hypofractionated

          -  Metastatic disease

          -  Patient deprived of liberty, under guardianship

          -  Any medical condition or psychological associate that could compromise the patient's
             ability to participate in the study

          -  Refusal of the patient.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>bernard GERY, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre François Baclesse</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre François BACLESSE</name>
      <address>
        <city>Caen</city>
        <zip>14076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2012</study_first_submitted>
  <study_first_submitted_qc>March 6, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2012</study_first_posted>
  <last_update_submitted>March 12, 2015</last_update_submitted>
  <last_update_submitted_qc>March 12, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 13, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>tomotherapy</keyword>
  <keyword>xerostomy</keyword>
  <keyword>head and neck squamous cell carcinoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Xerostomia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

